Medical Device FDA Regulatory Consulting Services

Accelerate your path to market with ProPharma's industry-leading medical device regulatory consulting services. Our team of former FDA officials, scientific experts, and regulatory strategists delivers unmatched guidance across the full device lifecycle—from premarket strategy through postmarket compliance.

Why Choose ProPharma for FDA Medical Device Consulting?

When it comes to navigating the complex FDA regulatory landscape, ProPharma offers unmatched expertise and strategic support to ensure your medical device reaches the market efficiently and compliantly.

Unparalleled Regulatory Expertise

ProPharma is home to the largest team of former FDA professionals and seasoned industry experts, bringing deep insight into the Agency's expectations, review processes, and evolving regulatory priorities. Our consultants have sat on both sides of the table, giving you a significant advantage in anticipating potential challenges and responding with confidence.

Proven Track Record of Success

With hundreds of successful FDA submissions and regulatory meetings under our belt, we have helped companies of all sizes—from emerging startups to global manufacturers—secure approvals across a wide range of device classifications and indications. Our strategic, detail-oriented approach drives results and minimizes costly delays.

Tailored Regulatory Strategies for Every Device

We understand that no two devices—or development programs—are the same. That’s why we build custom regulatory strategies that align with your product’s specific risk profile, innovation level, and commercial goals. Whether you’re developing a novel Class III implant or a software-based digital health tool, our team delivers the right expertise at the right time.

Comprehensive Lifecycle Support

From early-stage development and preclinical planning through FDA meetings, submission preparation, and postmarket compliance, ProPharma provides end-to-end regulatory support. Our integrated approach ensures continuity and compliance across every phase of your product’s lifecycle, helping you stay inspection-ready and aligned with FDA expectations.

Colorized half circle.
Regulatory Sciences Flywheel

Trusted FDA Experts for Medical Device Regulatory Strategy and Compliance

ProPharma is the trusted partner for navigating complex FDA regulatory pathways for medical devices, in vitro diagnostics (IVDs), and combination products. With deep expertise across all three categories, we help sponsors bring innovative products to market with speed, confidence, and compliance.

FDA Regulatory Medical Device Solutions

Our team of medical device and regulatory affairs experts create detailed strategies to move your product through the entire product lifecycle with ease.

Strategic FDA Regulatory Pathway Planning

Choosing the right FDA regulatory strategy is critical to the success of any medical device. Whether your product qualifies for a 510(k), De Novo, or PMA submission, our FDA consultants provide early pathway analysis, risk classification, and strategic planning to reduce regulatory hurdles and streamline your timeline to FDA clearance or approval.

It is essential to have a strategic and well-thought-out plan when preparing to approach the FDA for the clearance or approval of your medical device. Each interaction with the Agency should be carefully and tactically organized to maximize the information gained at each step in the process. A regulatory strategy provides the roadmap that you need.

Conference room strategy meeting with charts, graphs, and advanced technology

Each company and product are unique. Accordingly, the journey taken to obtain FDA approval will also be unique. ProPharma’s team of experienced medical device consultants understands this and develops customized regulatory strategies for every company and every product we work with, focusing on each client's individual needs.

At each step in development, you will gain new information and data that will construct and change the steps that follow. As this happens, your regulatory strategy must transform as well. When this happens, we will work with you to integrate any new information into your overall plan, even if we didn’t develop the initial strategy. We will audit and adjust your regulatory strategy to optimize the pathway to approval for your medical device.

FDA Meeting Support: Pre-Submissions, Q-Subs, and More

The goal of any FDA meeting is to get answers to critical questions and gain insight into the Agency's expectations. To achieve these goals, the meeting must be meticulously planned and executed impeccably, leaving FDA with the best impression of your medical device as well as your company. Making all of the pieces fit together requires the knowledge and experience of an expert. ProPharma's team of expert medical device consultants has the experience, knowledge, and expertise to ensure your FDA meeting is planned and conducted as seamlessly as possible. With more ex-FDA employees, coupled with our expansive team of industry executives and regulatory experts, our team will maximize your chances of successful interactions with the Agency.

Our team of medical device experts and regulatory consultants helps clients plan, prepare, and participate in:

  • Q-Submission (Q-sub) interactions, including: pre-submission (pre-sub) meetings, Submission Issue Requests (SIRs), and Informational Meetings
  • IDE, De Novo, and PMA discussions
  • Medical Device Advisory Committee meetings

We develop FDA-ready briefing packages, prepare your team for meetings, and provide expert representation and regulatory insight throughout the process.

FDA Submissions for Medical Devices

Before a medical device can be sold in the United States, it must often be evaluated and approved/cleared by the FDA's Center for Devices and Radiological Health (CDRH). This approval is achieved by submitting the appropriate application(s) based on your device’s classification. Regulatory requirements vary based on whether your product is a Class I, II, or III medical device. ProPharma’s Regulatory Sciences team can help you determine your device's classification and assist in the preparation and submission of the applicable application(s).

From concept through commercialization, we provide full-service support for FDA medical device submissions, including:

Hands typing on laptop displaying diagram of DNA double helix

  • 510(k) Premarket Notifications: we help determine predicate eligibility, prepare substantial equivalence rationales, guide testing strategies, and compile full submission content for Class II devices.
  • De Novo Classification Requests: for novel devices with no predicate, we guide you through this risk-based classification process, including pre-sub interactions, benefit-risk justifications, and development of special controls.
  • Premarket Approval (PMA) Applications: our team supports the most rigorous Class III submissions with robust scientific, clinical, and regulatory expertise, including pivotal study design, IDE support, and PMA module development.
  • Investigational Device Exemptions (IDE): We provide IDE strategy, protocol design, risk-benefit analysis, and submission preparation to obtain FDA approval for clinical investigations of high-risk devices.
  • Breakthrough Device Designation Requests: for eligible innovative products, we prepare compelling designations that emphasize the clinical need and transformative potential of your technology.
  • Humanitarian Device Exemption (HUD): for devices intended for rare conditions, we help navigate HDE requirements and FDA incentives for orphan products.

Our team ensures every submission is strategically crafted, fully compliant, and backed by sound scientific and regulatory rationale.

Our FDA submission consulting solutions include end-to-end services, such as:

  • Regulatory Pathway Determination: Helping you select the appropriate submission type and strategy based on product classification, risk, and novelty
  • Data Gap Analysis and Planning: Reviewing available data and identifying testing needs, labeling requirements, and evidence gaps
  • Content Authoring and Compilation: Writing and assembling all required modules, including:
    • Executive summaries
    • Device descriptions and specifications
    • Performance testing results (bench, animal, software)
    • Clinical data (if applicable)
    • Labeling and instructions for use (IFUs)
    • Biocompatibility and sterilization documentation
  • eSTAR and eCopy Preparation: Ensuring electronic submissions meet FDA formatting and technical requirements
  • Submission Review and Risk Mitigation: Conducting quality reviews, identifying potential issues, and strengthening justifications before submission
  • FDA Response Support: Assisting with additional information (AI) responses, deficiency letters, and real-time communication with FDA reviewers

Whether you're preparing your first 510(k) or navigating the complexities of a PMA or De Novo, ProPharma delivers the insight, precision, and regulatory rigor to get your medical device to market with confidence.

Preclinical and Biocompatibility Testing Strategy

group-of-healthcare-professionals-in-labcoats-pointing-to-a-test-tube-662x442

A strong preclinical testing program is foundational to regulatory success. Whether you are preparing a 510(k), De Novo, or PMA submission, FDA expects comprehensive evidence demonstrating your medical device is safe, performs as intended, and complies with applicable standards.

ProPharma helps clients design, optimize, and execute preclinical testing strategies that meet FDA requirements while avoiding unnecessary delays or costs.

Preclinical Testing Services Aligned with FDA and ISO Expectations

We support the full range of nonclinical testing activities, including:

  • Biocompatibility Testing (ISO 10993): we assess your device's materials and patient contact type to determine applicable biocompatibility endpoints. Our team guides the design and execution of testing programs—or justifies exemptions based on material characterization, literature, and historical data.
  • Bench and Performance Testing: from dimensional veriMedicalfication to functional testing under simulated use conditions, we help define and conduct appropriate bench testing strategies to validate safety and performance.
  • Electrical Safety and EMC Testing (IEC 60601): for electronic devices, we support comprehensive safety testing, including basic safety, essential performance, electromagnetic compatibility, and environmental stress evaluations.
  • Software Verification and Validation: for software-based or software-controlled devices, we help establish Software Level of Concern, develop testing protocols, and prepare documentation per FDA guidance and IEC 62304.
  • Usability and Human Factors Engineering: we assist in integrating usability testing into your design control process to reduce use errors and ensure alignment with FDA’s expectations under guidance for Human Factors in device design.
  • Sterilization Validation and Packaging Integrity: we guide clients in meeting requirements for sterilization methods (e.g., EO, gamma, steam), SAL validation, and package shelf-life testing per ISO 11607 and FDA-recognized standards.
  • Animal Studies: when required, we support preclinical in vivo studies to evaluate safety and biological response, including protocol development, CRO management, and data interpretation.

Reimbursement Strategy and Market Access Planning

Regulatory approval alone doesn’t guarantee market success. We integrate reimbursement consulting into your regulatory plan to help you secure:

  • Medicare and commercial payer coverage
  • Appropriate CPT and HCPCS codes
  • Viable payment pathways and pricing strategy

By aligning your FDA and reimbursement strategies early, we help you reduce barriers to adoption and optimize market access.

Postmarket Regulatory Compliance

Achieving FDA approval is only the beginning. ProPharma supports clients in maintaining compliance with postmarket regulatory requirements, including:

  • FDA Medical Device Reporting (MDR)
  • Post-Approval Studies (PAS)
  • Recalls, corrections, and removals
  • Annual reports and regulatory updates
  • Labeling and promotional compliance

We also assist with FDA inspections, enforcement actions, and global market expansion strategies.

healthcare-workers-labcoats-reviewing-papers-near-computer-monitor-ss-46716574-650x425

 

ProPharma: The World's Leading Regulatory Consultancy

Interested in learning how we can help with your medical device regulatory needs? Contact us today to learn about our track record of success with FDA over the last 40 years and discuss how we can help get your medical device to the next regulatory milestone and achieve your regulatory goals.

Thumbnail Image for Overworked Medical Device Teams Missing Deadlines

News & Insights

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guide for Marketing Authorization Holders (MAHs)

July 25, 2025

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guid...

Learn about the crucial roles of QPPV, LPPV, and PSMF in ensuring effective pharmacovigilance and regulatory compliance for Marketing Authorization Holders (MAHs).

FDA Publishes over 200 Complete Response Letters (CRLs)

July 24, 2025

FDA Publishes over 200 Complete Response Letters (CRLs)

FDA's new transparency with over 200 CRLs empowers sponsors to navigate regulatory challenges more effectively, accelerating drug approvals and enhancing patient access to treatments.

Navigating EMA and Global Regulations for Medical Information Services

July 24, 2025

Navigating EMA and Global Regulations for Medical Information Services

ProPharma guides clients through global medical information regulatory landscapes, ensuring compliance and excellence across markets with tailored solutions, AI integration, and continuous training.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study From Drafts to First Patient in Record Time - ProPharma

July 8, 2025

From Drafts to First Patient in Record Time

Launching a global clinical study from draft documents, the team achieved US first patient in in 3.5 months and met ambitious global submission timelines. Strong collaboration, proactive planning,...

Whitepapers FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submission

June 23, 2025

FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submiss...

A Strategic Guide to Early FDA Engagement for a Streamlined NDA Pathway For drug developers leveraging the 505(b)(2) NDA pathway, early engagement with FDA is a critical determinant of regulatory...

Case Study Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina - ProPharma

June 18, 2025

Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina

Acting as Marketing Authorization Holder in Bosnia and Herzegovina, Clinres—a ProPharma company—helped a global pharma client overcome regulatory delays, misaligned planning, and seasonal launch...

Avoiding Common Pitfalls During FDA Inspections

July 29, 2025

Avoiding Common Pitfalls During FDA Inspections

Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

July 22, 2025

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...

MAH Essentials: Ensuring Compliance for European Market Entry

July 10, 2025

MAH Essentials: Ensuring Compliance for European Market Entry

This webinar covers the key responsibilities of Marketing Authorization Applicants/Holders and Qualified Persons in the EEA/UK, including pharmacovigilance requirements, legal entity setup, and...

News & Insights

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guide for Marketing Authorization Holders (MAHs)

July 25, 2025

Understanding the Roles of LPPV, QPPV, and the PSMF in Pharmacovigilance: A Guid...

Learn about the crucial roles of QPPV, LPPV, and PSMF in ensuring effective pharmacovigilance and regulatory compliance for Marketing Authorization Holders (MAHs).

FDA Publishes over 200 Complete Response Letters (CRLs)

July 24, 2025

FDA Publishes over 200 Complete Response Letters (CRLs)

FDA's new transparency with over 200 CRLs empowers sponsors to navigate regulatory challenges more effectively, accelerating drug approvals and enhancing patient access to treatments.

Navigating EMA and Global Regulations for Medical Information Services

July 24, 2025

Navigating EMA and Global Regulations for Medical Information Services

ProPharma guides clients through global medical information regulatory landscapes, ensuring compliance and excellence across markets with tailored solutions, AI integration, and continuous training.

Previous Post Arrow Next Post Arrow
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study From Drafts to First Patient in Record Time - ProPharma

July 8, 2025

From Drafts to First Patient in Record Time

Launching a global clinical study from draft documents, the team achieved US first patient in in 3.5 months and met ambitious global submission timelines. Strong collaboration, proactive planning,...

Whitepapers FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submission

June 23, 2025

FDA Pre-IND Meetings: Setting Yourself up For a Successful 505(b)(2) NDA Submiss...

A Strategic Guide to Early FDA Engagement for a Streamlined NDA Pathway For drug developers leveraging the 505(b)(2) NDA pathway, early engagement with FDA is a critical determinant of regulatory...

Case Study Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina - ProPharma

June 18, 2025

Local Expertise, Local Knowledge: MAH in Bosnia and Herzegovina

Acting as Marketing Authorization Holder in Bosnia and Herzegovina, Clinres—a ProPharma company—helped a global pharma client overcome regulatory delays, misaligned planning, and seasonal launch...

Previous Resource Arrow Next Resource Arrow
Avoiding Common Pitfalls During FDA Inspections

July 29, 2025

Avoiding Common Pitfalls During FDA Inspections

Starting August 2025, the FDA will conduct unannounced inspections at non-U.S. sites. This webinar explores common inspection pitfalls and how to maintain global inspection readiness with expert...

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

July 22, 2025

Inside FDA Review: Crafting a Quality ANDA Labeling Submission

Gain rare, insider insight into the FDA’s expectations for ANDA submissions in this session led by Marshall Florence, PharmD, a former FDA reviewer who recently joined our team. With firsthand...

MAH Essentials: Ensuring Compliance for European Market Entry

July 10, 2025

MAH Essentials: Ensuring Compliance for European Market Entry

This webinar covers the key responsibilities of Marketing Authorization Applicants/Holders and Qualified Persons in the EEA/UK, including pharmacovigilance requirements, legal entity setup, and...

Previous Webinar Arrow Next Webinar Arrow